Journal of Pharmaceutical Innovation

, Volume 11, Issue 2, pp 109–119 | Cite as

Influence of Soluplus on Solid-State Properties and Physical Stability of Indomethacin-Saccharin Co-crystal Formation Prepared by Air-Drying Process

  • Shan-Yang LinEmail author
  • Hong-Liang Lin
  • Ying-Ting Chi
  • Ru-Ying Hung
  • Yu-Ting Huang
  • Wei-Hsien Hsieh
  • Chi-Yu Kao
Original Article



The effect of Soluplus on the solid-state characteristics and physical transformation of indomethacin (IMC), saccharin (SAC), IMC-SAC physical mixture, and the previously prepared IMC-SAC co-crystal was investigated after solvent evaporation via air-drying process.


Soluplus with γ-IMC or SAC (weight ratio = 1:1) was respectively prepared by completely dissolving both components in acetone by ultrasonication, and then evaporated via air-drying process. Soluplus was fully co-dissolved with the previously prepared IMC-SAC co-crystal (procedure I) or completely dissolved together with IMC-SAC physical mixture (procedure II) in acetone by ultrasonication, and then evaporated through air-drying process. The physical stability of both Soluplus/IMC-SAC systems was also carried out under accelerated storage conditions. All the samples were determined by thermoanalytical and FTIR spectroscopic studies with spectral curve-fitting technique.


Soluplus caused the amorphous formation of IMC or SAC in the Soluplus solid dispersion, in which the intermolecular hydrogen bonding interaction between SAC and Soluplus occurred. Although Soluplus did not influence the co-crystal formation between IMC and SAC in the solid dispersion, the polymorphic transformation and physical stability of Soluplus/IMC-SAC solid dispersion were markedly influenced by procedures I and II after evaporation via air-drying process.


Soluplus influences the amorphous or crystalline IMC-SAC co-crystal formulated in the solid dispersion prepared by procedure I or II via air-drying process. The amorphous IMC-SAC co-crystal in the Soluplus solid dispersion prepared by procedure I gradually transformed to a crystalline IMC-SAC co-crystal after storage at 40 ± 2 °C/75 ± 5 % RH conditions for 28 days, whereas the crystalline IMC-SAC co-crystal in the Soluplus solid dispersion prepared by procedure II via air-drying process maintained a long-term storage stability.


Soluplus Indomethacin (IMC) Saccharin (SAC) Solid dispersion Co-crystal Stability Amorphous Crystalline Storage 



This work was supported by Ministry of Science and Technology, Taipei, Taiwan, ROC (MOST 103-2320-B-264-002-MY2).

Compliance with Ethical Standards

Conflict of Interest

The authors declare no competing financial interest.


  1. 1.
    Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9:2950–67.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals: an opportunity for drug product enhancement. Expert Opin Drug Deliv. 2009;6:333–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm. 2011;419:1–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Almarsson Ö, Peterson ML, Zaworotko M. The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents. Pharm Pat Anal. 2012;1:313–27.CrossRefPubMedGoogle Scholar
  5. 5.
    Trask AV. An overview of pharmaceutical cocrystals as intellectual property. Mol Pharm. 2007;4:301–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Brittain HG. Pharmaceutical cocrystals: the coming wave of new drug substances. J Pharm Sci. 2013;102:311–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Chadha R, Saini A, Arora P, Bhandari S. Pharmaceutical cocrystals: a novel approach for oral bioavailability enhancement of drugs. Crit Rev Ther Drug Carrier Syst. 2012;29:183–218.CrossRefPubMedGoogle Scholar
  8. 8.
    Sekhon BS. Drug-drug co-crystals. Daru. 2012;20:45.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ghadi R, Ghuge A, Ghumre S, Waghmare N, Kadam DVJ. Co-crystals: emerging approach in pharmaceutical design. Indo Am J Pharm Res. 2014;4:3881–93.Google Scholar
  10. 10.
    US FDA. Regulatory classification of pharmaceutical co-crystals, 2013.Google Scholar
  11. 11.
    Yadav AV, Shete AS, Dabke AP, Kulkarni PV, Sakhare SS. Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients. Indian J Pharm Sci. 2009;71:359–70.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Nangia A, Desiraju GR. Supramolecular synthons and pattern recognition. Des Org Solids. 1998;198:57–95.CrossRefGoogle Scholar
  13. 13.
    Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Bán M, Bombicz P, Madarász J. Thermal stability and structure of a new co-crystal of theophylline formed with phthalic acid. J Therm Anal Calorim. 2009;95:895–901.CrossRefGoogle Scholar
  15. 15.
    Jayasankar A, Roy L, Rodríguez-Hornedo N. Transformation pathways of cocrystal hydrates when coformer modulates water activity. J Pharm Sci. 2010;99:3977–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Eddleston MD, Thakuria R, Aldous BJ, Jones W. An investigation of the causes of cocrystal dissociation at high humidity. J Pharm Sci. 2014;103:2859–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Bevernage J, Forier T, Brouwers J, Tack J, Annaert P, Augustijns P. Excipient-mediated supersaturation stabilization in human intestinal fluids. Mol. Pharm. 2011;8564-70.Google Scholar
  18. 18.
    Gao P, Shi Y. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J. 2012;14:703–13.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Curatolo W, Nightingale JA, Herbig SM. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res. 2009;26:1419–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Surwase SA, Itkonen L, Aaltonen J, Saville D, Rades T, Peltonen L, Strachan CJ. Polymer incorporation method affects the physical stability of amorphous indomethacin in aqueous suspension. Eur J Pharm Biopharm. 2015.Google Scholar
  21. 21.
    Li M, Qiu S, Lu Y, Wang K, Lai X, Rehan M. Investigation of the effect of hydroxypropyl methylcellulose on the phase transformation and release profiles of carbamazepine-nicotinamide cocrystal. Pharm Res. 2014;31:2312–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Boksa K, Otte A, Pinal R. Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion. J Pharm Sci. 2014;103:2904–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal’s potential. Mol Pharm. 2007;4:386–400.CrossRefPubMedGoogle Scholar
  24. 24.
    Childs SL, Kandi P, Lingireddy SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm. 2013;10:3112–27.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang GC, Lin HL, Lin SY. Thermal analysis and FTIR spectral curve-fitting investigation of formation mechanism and stability of indomethacin-saccharin cocrystals via solid-state grinding process. J Pharm Biomed Anal. 2012;66:162–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Lin HL, Zhang GC, Hsu PC, Lin SY. A portable fiber-optic Raman analyzer for fast real-time screening and identifying cocrystal formation of drug-coformer via grinding process. Microchem J. 2013;110:15–20.CrossRefGoogle Scholar
  27. 27.
    Lin HL, Zhang GC, Lin SY. Real-time co-crystal screening and formation between indomethacin and saccharin via DSC analytical technique or DSC-FTIR microspectroscopy. J Therm Anal Calorim. 2015;120:679–87.CrossRefGoogle Scholar
  28. 28.
    Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res. 2008;25:530–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Alhalaweh A, Roy L, Rodríguez-Hornedo N, Velaga SP. pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media. Mol Pharm. 2012;9:2605–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Reintjes T. Solubility enhancement with BASF pharma polymers: solubilizer compendium. Germany: BASF SE Pharma Ingredients & Services; 2011.Google Scholar
  31. 31.
    Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technol. 2013;237:406–14.CrossRefGoogle Scholar
  32. 32.
    Terife G, Wang P, Faridi N, Gogos GC. Hot melt mixing and foaming of Soluplus® and indomethacin. Polym Eng Sci. 2012;52:1629–39.CrossRefGoogle Scholar
  33. 33.
    Lin SY, Hsu CH, Sheu MT. Curve-fitting FTIR studies of loratadine/hydroxypropyl-β-cyclodextrin inclusion complex induced by co-grinding process. J Pharm Biomed Anal. 2010;53:799–803.CrossRefPubMedGoogle Scholar
  34. 34.
    Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14:1691–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Kao CY, Huang HH, Huang YT, Lin LH, Lin SY. Thermoanalytical and spectroscopic studies on amorphization and phase transition of amorphous indomethacin prepared by two melt-cooling processes. ScienceJet. 2015;4:148.Google Scholar
  36. 36.
    Greco K, Bogner R. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing. Mol Pharm. 2010;7:1406–18.CrossRefPubMedGoogle Scholar
  37. 37.
    Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. Int J Pharm. 2011;417:94–100.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang Y. Spectral and thermal properties of saccharin and saccharin metal complexes. Transit Met Chem. 1994;19:446–8.CrossRefGoogle Scholar
  39. 39.
    Binev IG, Stamboliyska BA, Velcheva EA. The infrared spectra and structure of o-sulfobenzimide (saccharin) and of its nitranion: an ab initio force field treatment. Spectrochim Acta Part A. 1996;52:1135–43.CrossRefGoogle Scholar
  40. 40.
    Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. Soluplus—solubilized citrated camptothecin—a potential drug delivery strategy in colon cancer. AAPS PharmSciTech. 2012;13:59–66.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nanjwade VK, Manvi FV, Ali SM, Nanjwade BK, Maste MM. New trend in the cocrystallization of active pharmaceutical ingredient. J Appl Pharm Sci. 2011;8:1–5.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Shan-Yang Lin
    • 1
    Email author
  • Hong-Liang Lin
    • 1
  • Ying-Ting Chi
    • 1
  • Ru-Ying Hung
    • 1
  • Yu-Ting Huang
    • 1
  • Wei-Hsien Hsieh
    • 1
  • Chi-Yu Kao
    • 1
  1. 1.Department of Biotechnology and Pharmaceutical TechnologyYuanpei University of Medical TechnologyHsin ChuRepublic of China

Personalised recommendations